MA45189A - Nouveaux dérivés hétérocycliques utiles en tant qu'inhibiteurs de shp2 - Google Patents

Nouveaux dérivés hétérocycliques utiles en tant qu'inhibiteurs de shp2

Info

Publication number
MA45189A
MA45189A MA045189A MA45189A MA45189A MA 45189 A MA45189 A MA 45189A MA 045189 A MA045189 A MA 045189A MA 45189 A MA45189 A MA 45189A MA 45189 A MA45189 A MA 45189A
Authority
MA
Morocco
Prior art keywords
derivatives useful
heterocyclic derivatives
new heterocyclic
shp2 inhibitors
shp2
Prior art date
Application number
MA045189A
Other languages
English (en)
Inventor
Jinlong Bai
Jie Chu
Panliang Gao
Di Kang
Cunbo Ma
Xiaoyan Pei
Chunwei Wen
Xinping Wu
Original Assignee
Jacobio Pharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jacobio Pharmaceuticals Co Ltd filed Critical Jacobio Pharmaceuticals Co Ltd
Publication of MA45189A publication Critical patent/MA45189A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
MA045189A 2016-06-07 2017-06-07 Nouveaux dérivés hétérocycliques utiles en tant qu'inhibiteurs de shp2 MA45189A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2016085122 2016-06-07

Publications (1)

Publication Number Publication Date
MA45189A true MA45189A (fr) 2019-04-10

Family

ID=60578379

Family Applications (1)

Application Number Title Priority Date Filing Date
MA045189A MA45189A (fr) 2016-06-07 2017-06-07 Nouveaux dérivés hétérocycliques utiles en tant qu'inhibiteurs de shp2

Country Status (23)

Country Link
US (1) US10858359B2 (fr)
EP (2) EP4108659A1 (fr)
JP (3) JP6751203B2 (fr)
KR (5) KR102218333B1 (fr)
CN (3) CN114539273A (fr)
AU (1) AU2017276457B2 (fr)
CA (1) CA3026784A1 (fr)
CY (1) CY1125042T1 (fr)
DK (1) DK3464272T3 (fr)
EA (3) EA202092442A3 (fr)
ES (1) ES2908801T3 (fr)
HR (1) HRP20220251T1 (fr)
HU (1) HUE057838T2 (fr)
LT (1) LT3464272T (fr)
MA (1) MA45189A (fr)
MX (3) MX388576B (fr)
PH (1) PH12018550202A1 (fr)
PL (1) PL3464272T3 (fr)
PT (1) PT3464272T (fr)
RS (1) RS62987B1 (fr)
SG (2) SG10202110874TA (fr)
SI (1) SI3464272T1 (fr)
WO (1) WO2017211303A1 (fr)

Families Citing this family (160)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11466017B2 (en) 2011-03-10 2022-10-11 Board Of Regents, The University Of Texas System Heterocyclic inhibitors of PTPN11
JO3517B1 (ar) 2014-01-17 2020-07-05 Novartis Ag ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
CA3024706A1 (fr) 2016-05-31 2017-12-07 Board Of Regents, The University Of Texas System Inhibiteurs heterocycliques de ptpn11
KR102218333B1 (ko) * 2016-06-07 2021-02-22 자코바이오 파마슈티칼스 컴퍼니 리미티드 Shp2 억제제로서 유용한 신규한 헤테로환형 유도체
RU2021106500A (ru) * 2016-06-14 2021-04-16 Новартис Аг Соединения и композиции для подавления активности shp2
SG11201900157RA (en) 2016-07-12 2019-02-27 Revolution Medicines Inc 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric shp2 inhibitors
US11529347B2 (en) 2016-09-22 2022-12-20 Relay Therapeutics, Inc. SHP2 phosphatase inhibitors and methods of use thereof
TW202500565A (zh) 2016-10-24 2025-01-01 美商傳達治療有限公司 Shp2磷酸酶抑制劑及其使用方法
AU2018210196B2 (en) 2017-01-23 2022-06-02 Revolution Medicines, Inc. Pyridine compounds as allosteric SHP2 inhibitors
JP7240319B2 (ja) 2017-01-23 2023-03-15 レヴォリューション・メディスンズ，インコーポレイテッド アロステリックｓｈｐ２阻害剤としての二環式化合物
HRP20241239T1 (hr) * 2017-03-23 2024-12-06 Jacobio Pharmaceuticals Co., Ltd. Novi heterociklički derivati korisni kao shp2 inhibitori
US11591336B2 (en) 2017-05-26 2023-02-28 D. E. Shaw Research, Llc Substituted pyrazolo[3,4-b]pyrazines as SHP2 phosphatase inhibitors
AU2018328273A1 (en) 2017-09-07 2020-03-12 Revolution Medicines, Inc. SHP2 inhibitor compositions and methods for treating cancer
CN111201223B (zh) 2017-09-11 2024-07-09 克鲁松制药公司 SHP2的八氢环戊二烯并[c]吡咯别构抑制剂
WO2019067843A1 (fr) 2017-09-29 2019-04-04 Relay Therapeutics, Inc. Dérivés de pyrazolo[3,4-b]pyrazine utilisés en tant qu'inhibiteurs de la phosphatase shp2
BR112020007058A2 (pt) 2017-10-12 2020-10-06 Revolution Medicines, Inc. compostos de piridina, pirazina, e triazina como inibidores de shp2 alostéricos
MX2020006273A (es) 2017-12-15 2020-09-14 Revolution Medicines Inc Compuestos policiclicos como inhibidores alostericos de shp2.
EP3753941B1 (fr) 2018-02-13 2024-05-01 Shanghai Blueray Biopharma Co., Ltd. Composé cyclique fusionné à une pyrimidine, son procédé de préparation et son application
KR102753101B1 (ko) 2018-03-02 2025-01-09 오츠카 세이야쿠 가부시키가이샤 약제학적 화합물
US10561655B2 (en) 2018-03-21 2020-02-18 Synblia Therapeutics, Inc. SHP2 inhibitors and uses thereof
BR112020019385A2 (pt) * 2018-03-21 2021-03-30 Relay Therapeutics, Inc. Inibidores de shp2 fosfatase e métodos de uso dos mesmos
WO2019183364A1 (fr) 2018-03-21 2019-09-26 Relay Therapeutics, Inc. Inhibiteurs de la phosphatase pyrazolo[3,4-b]pyrazine shp2 et leurs procédés d'utilisation
MX2020010719A (es) 2018-04-10 2020-11-06 Revolution Medicines Inc Composiciones de inhibidores de shp2, metodos para tratar el cancer y metodos para identificar a un sujeto con mutaciones en shp2.
KR102611661B1 (ko) 2018-05-02 2023-12-08 나비레 파르마, 인코퍼레이티드 Ptpn11의 치환된 헤테로사이클릭 억제제
CN112174935B (zh) * 2018-05-09 2022-12-06 北京加科思新药研发有限公司 可用作shp2抑制剂的杂环衍生物
KR102579709B1 (ko) 2018-07-24 2023-09-15 다이호야쿠힌고교 가부시키가이샤 Shp2의 활성을 억제하기 위한 헤테로이환식 화합물
IL307361B2 (en) 2018-08-10 2024-12-01 Navire Pharma Inc 6-(4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-3-(2,3-dichlorophenyl)-2-methylpyrimidin-4(3h)-one derivatives and related compounds as ptpn11 (shp2) inhibitors for treating cancer
BR112021005082A2 (pt) 2018-09-18 2021-06-08 Nikang Therapeutics, Inc. derivados de anel tricíclico fundido como inibidores de src homologia-2 fosfatase
US20210393623A1 (en) * 2018-09-26 2021-12-23 Jacobio Pharmaceuticals Co., Ltd. Novel Heterocyclic Derivatives Useful as SHP2 Inhibitors
WO2020065453A1 (fr) * 2018-09-29 2020-04-02 Novartis Ag Procédé de fabrication d'un composé pour inhiber l'activité de shp2
CA3112322A1 (fr) 2018-09-29 2020-04-02 Novartis Ag Fabrication de composes et de compositions pour inhiber l'activite de shp2
US11179397B2 (en) 2018-10-03 2021-11-23 Gilead Sciences, Inc. Imidazopyrimidine derivatives
WO2020076723A1 (fr) 2018-10-08 2020-04-16 Revolution Medicines, Inc. Compositions d'inhibiteurs de shp2 destinées à être utilisées dans le traitement du cancer
TW202028183A (zh) * 2018-10-10 2020-08-01 大陸商江蘇豪森藥業集團有限公司 含氮雜芳類衍生物調節劑、其製備方法和應用
HUE062404T2 (hu) 2018-10-17 2023-10-28 Array Biopharma Inc Protein tirozin foszfatáz inhibitorok
CN117143079A (zh) * 2018-11-06 2023-12-01 上海奕拓医药科技有限责任公司 一种螺芳环化合物及其应用
WO2020108590A1 (fr) 2018-11-30 2020-06-04 上海拓界生物医药科技有限公司 Pyrimidine et dérivé hétérocycle pentagonal de nitrogène, leur procédé de préparation et applications médicales
JP2022509724A (ja) 2018-12-05 2022-01-24 ミラティ セラピューティクス， インコーポレイテッド 組み合わせ療法
WO2020180768A1 (fr) 2019-03-01 2020-09-10 Revolution Medicines, Inc. Composés hétéroaryle bicycliques et leurs utilisations
MX2021010323A (es) 2019-03-01 2021-12-10 Revolution Medicines Inc Compuestos bicíclicos de heterociclilo y usos de este.
CN111647000B (zh) * 2019-03-04 2021-10-12 勤浩医药（苏州）有限公司 吡嗪类衍生物及其在抑制shp2中的应用
JP7734586B2 (ja) 2019-03-07 2025-09-05 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｓｈｐ２アンタゴニストとしてのカルボキサミド－ピリミジン誘導体
PE20220141A1 (es) 2019-04-02 2022-01-27 Array Biopharma Inc Inhibidores de la proteina tirosina fosfatasa
CA3127475A1 (fr) 2019-04-08 2020-10-15 Merck Patent Gmbh Derives de pyrimidinone utilises en tant qu'antagonistes de shp2
TWI826690B (zh) 2019-05-23 2023-12-21 美商基利科學股份有限公司 經取代之烯吲哚酮化物及其用途
NZ783169A (en) 2019-06-25 2024-12-20 Gilead Sciences Inc Flt3l-fc fusion proteins and methods of use
KR20220054285A (ko) * 2019-06-28 2022-05-02 투오지에 바이오텍 (상하이) 컴퍼니 리미티드 피리미딘 5 원 질소 헤테로고리형 유도체, 이의 제조 방법 및 이의 약학적 용도
CN111704611B (zh) * 2019-07-25 2022-01-14 上海凌达生物医药有限公司 一类芳基螺环类shp2抑制剂化合物、制备方法和用途
EP3772513A1 (fr) 2019-08-09 2021-02-10 C.N.C.C.S. S.c.a.r.l. Collezione Nazionale Dei Composti Chimici e Centro Screening Inhibiteurs d'shp2
GB201911928D0 (en) 2019-08-20 2019-10-02 Otsuka Pharma Co Ltd Pharmaceutical compounds
CN114127053B (zh) * 2019-09-06 2023-06-13 四川科伦博泰生物医药股份有限公司 一种取代吡嗪化合物、其制备方法和用途
TW202126660A (zh) 2019-09-24 2021-07-16 美商傳達治療有限公司 Ｓｈｐ２磷酸酶抑制劑及其製備與使用方法
CN112724145A (zh) * 2019-10-14 2021-04-30 杭州雷索药业有限公司 用于抑制shp2活性的吡嗪衍生物
AU2020365113B2 (en) 2019-10-18 2025-04-24 Forty Seven, LLC Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia
US20210147568A1 (en) 2019-10-31 2021-05-20 Forty Seven, Inc. Anti-cd47 based treatment of blood cancer
CN115873020B (zh) 2019-11-04 2025-06-13 锐新医药公司 Ras抑制剂
WO2021091982A1 (fr) 2019-11-04 2021-05-14 Revolution Medicines, Inc. Inhibiteurs de ras
CA3160142A1 (fr) 2019-11-04 2021-05-14 Revolution Medicines, Inc. Inhibiteurs de ras
PE20230249A1 (es) 2019-11-08 2023-02-07 Revolution Medicines Inc Compuestos de heteroarilo biciclicos y usos de estos
TWI778443B (zh) 2019-11-12 2022-09-21 美商基利科學股份有限公司 Mcl1抑制劑
EP4065231A1 (fr) 2019-11-27 2022-10-05 Revolution Medicines, Inc. Inhibiteurs de ras covalents et leurs utilisations
SI4081305T1 (sl) 2019-12-24 2025-03-31 Carna Biosciences, Inc. Spojine, ki modulirajo diacilglicerol kinazo
WO2021142026A1 (fr) 2020-01-07 2021-07-15 Revolution Medicines, Inc. Dosage d'inhibiteurs de shp2 et méthodes de traitement du cancer
CN113135910A (zh) * 2020-01-19 2021-07-20 北京诺诚健华医药科技有限公司 嘧啶-4(3h)-酮类杂环化合物、其制备方法及其在医药学上的应用
WO2021163064A2 (fr) 2020-02-14 2021-08-19 Jounce Therapeutics, Inc. Anticorps et protéines de fusion se liant à ccr8, et leurs utilisations
US20230090389A1 (en) 2020-02-28 2023-03-23 Novartis Ag A triple pharmaceutical combination comprising dabrafenib, an erk inhibitor and a shp2 inhibitor
CN115362149B (zh) * 2020-04-26 2024-05-14 贝达药业股份有限公司 Shp2抑制剂及其组合物和应用
WO2021218755A1 (fr) * 2020-04-30 2021-11-04 贝达药业股份有限公司 Inhibiteur de shp2, et composition et utilisation de celui-ci
EP4143194A1 (fr) 2020-05-01 2023-03-08 Gilead Sciences, Inc. Composés de 2,4-dioxopyrimidine inhibant cd73
CN113754683A (zh) 2020-06-05 2021-12-07 上海奕拓医药科技有限责任公司 同位素取代的螺芳环化合物及其应用
TW202214253A (zh) 2020-06-18 2022-04-16 美商銳新醫藥公司 延遲、預防及治療對ｒａｓ抑制劑之後天抗性之方法
EP4169913A4 (fr) * 2020-06-22 2024-10-30 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Composé de pyrazine substitué, composition pharmaceutique le comprenant et utilisation associée
JP7729870B2 (ja) 2020-07-08 2025-08-26 ノバルティス アーゲー Ｓｈｐ２の活性を阻害するための化合物及び組成物の製造
CN116209438A (zh) 2020-09-03 2023-06-02 锐新医药公司 使用sos1抑制剂治疗具有shp2突变的恶性疾病
JP7832184B2 (ja) 2020-09-15 2026-03-17 レヴォリューション・メディスンズ，インコーポレイテッド がんの治療における、ｒａｓ阻害剤としてのインドール誘導体
AR124449A1 (es) 2020-12-22 2023-03-29 Qilu Regor Therapeutics Inc Inhibidores de sos1 y usos de los mismos
EP4039685A1 (fr) 2021-02-08 2022-08-10 Irbm S.P.A. Inhibiteurs azabicycliques de shp2
CA3213837A1 (fr) * 2021-03-23 2022-09-29 Shanghai Haiyan Pharmaceutical Technology Co., Ltd. Derive de cetone substitue par un heterocycle, et composition et son utilisation medicinale
EP4067358A1 (fr) 2021-04-02 2022-10-05 C.N.C.C.S. S.c.a.r.l. Collezione Nazionale Dei Composti Chimici e Centro Screening Dérivés de (s)-1-(5-((pyridin-3-yl)thio)pyrazin-2-yl)-4'h,6'h-spiro[pipéridine-4,5'-pyrrolo[1,2-b]pyrazol]-4'-amine et composés similaires en tant qu'inhibiteurs de shp2 pour le traitement par ex. du cancer
TW202302145A (zh) 2021-04-14 2023-01-16 美商基利科學股份有限公司 ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症
CN117500811A (zh) 2021-05-05 2024-02-02 锐新医药公司 共价ras抑制剂及其用途
CA3217084A1 (fr) 2021-05-05 2022-11-10 Farbod Shojaei Polytherapies comprenant des inhibiteurs de shp2 et des inhibiteurs de pd-1
AR125787A1 (es) 2021-05-05 2023-08-16 Revolution Medicines Inc Inhibidores de ras
WO2022235822A1 (fr) 2021-05-05 2022-11-10 Huabio International, Llc Monothérapie d'inhibiteur de shp2 et ses utilisations
PE20240088A1 (es) 2021-05-05 2024-01-16 Revolution Medicines Inc Inhibidores de ras
WO2022237367A1 (fr) * 2021-05-13 2022-11-17 中国科学院上海药物研究所 Composé hétérocyclique pour inhiber l'activité de shp2, son procédé de préparation et son utilisation
WO2022245671A1 (fr) 2021-05-18 2022-11-24 Gilead Sciences, Inc. Méthodes d'utilisation de protéines de fusion flt3l-fc
TW202313041A (zh) 2021-06-09 2023-04-01 瑞士商諾華公司 包含達拉菲尼、曲美替尼和shp2抑制劑之三重藥物組合
AU2022297373B2 (en) 2021-06-23 2025-04-17 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
CA3222439A1 (fr) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Composes modulant les diacylglycerol kinases
TW202317100A (zh) 2021-06-23 2023-05-01 瑞士商諾華公司 包含ｋｒａｓ ｇ１２ｃ抑制劑的藥物組合及其用於治療癌症之用途
CA3222277A1 (fr) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Composes modulant les diacylglycerol kinases
WO2022271650A1 (fr) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Composés de modulation de la diacylglycérol kinase
KR102682323B1 (ko) * 2021-07-09 2024-07-09 주식회사 카나프테라퓨틱스 Shp2 억제제 및 이의 용도
CN117916242A (zh) * 2021-07-09 2024-04-19 治纳辅医药科技有限公司 Shp2抑制剂及其用途
CN113461538A (zh) * 2021-07-12 2021-10-01 无锡双启科技有限公司 一种2-氯-3-溴苯胺的制备方法
US20240374571A1 (en) 2021-09-01 2024-11-14 Novartis Ag Pharmaceutical combinations comprising a tead inhibitor and uses thereof for the treatment of cancers
AR127308A1 (es) 2021-10-08 2024-01-10 Revolution Medicines Inc Inhibidores ras
CA3234909A1 (fr) 2021-10-28 2023-05-04 Gilead Sciences, Inc. Derives de pyridine-3(2h)-one
JP7787991B2 (ja) 2021-10-29 2025-12-17 ギリアード サイエンシーズ， インコーポレイテッド Ｃｄ７３化合物
US20230220106A1 (en) 2021-12-08 2023-07-13 Dragonfly Therapeutics, Inc. Antibodies targeting 5t4 and uses thereof
WO2023107956A1 (fr) 2021-12-08 2023-06-15 Dragonfly Therapeutics, Inc. Protéines se liant à nkg2d, cd16 et 5t4
WO2023122615A1 (fr) 2021-12-22 2023-06-29 Gilead Sciences, Inc. Agents de dégradation des doigts de zinc de la famille ikaros et leurs utilisations
JP2024546851A (ja) 2021-12-22 2024-12-26 ギリアード サイエンシーズ， インコーポレイテッド Ｉｋａｒｏｓジンクフィンガーファミリー分解剤及びその使用
WO2023122938A1 (fr) * 2021-12-28 2023-07-06 Js Innomed Holdings Ltd. Composés hétérocycliques utilisés en tant qu'inhibiteurs de shp2, compositions comprenant le composé hétérocyclique, et leurs procédés d'utilisation
TW202340168A (zh) 2022-01-28 2023-10-16 美商基利科學股份有限公司 Ｐａｒｐ７抑制劑
EP4489755A1 (fr) 2022-03-08 2025-01-15 Revolution Medicines, Inc. Méthodes de traitement du cancer du poumon réfractaire immunitaire
WO2023169170A1 (fr) * 2022-03-10 2023-09-14 捷思英达控股有限公司 Composé hétérocyclique utilisé en tant qu'inhibiteur de shp2, composition comprenant un composé hétérocyclique, et procédé l'utilisant
TW202346277A (zh) 2022-03-17 2023-12-01 美商基利科學股份有限公司 Ｉｋａｒｏｓ鋅指家族降解劑及其用途
EP4499146A1 (fr) 2022-03-24 2025-02-05 Gilead Sciences, Inc. Polythérapie pour le traitement de cancers exprimant trop -2
TWI876305B (zh) 2022-04-05 2025-03-11 美商基利科學股份有限公司 用於治療結腸直腸癌之組合療法
JP2025513258A (ja) 2022-04-21 2025-04-24 ギリアード サイエンシーズ， インコーポレイテッド Ｋｒａ ｇ１２ｄ調節化合物
JP2025519119A (ja) 2022-05-25 2025-06-24 イケナ オンコロジー， インコーポレイテッド Ｍｅｋ阻害剤及びその使用
IL317476A (en) 2022-06-10 2025-02-01 Revolution Medicines Inc Macrocyclic RAS inhibitors
AU2023298558A1 (en) 2022-07-01 2024-12-19 Gilead Sciences, Inc. Cd73 compounds
EP4573095A1 (fr) 2022-08-17 2025-06-25 Treeline Biosciences, Inc. Inhibiteurs de pyridopyrimidine kras
WO2024064668A1 (fr) 2022-09-21 2024-03-28 Gilead Sciences, Inc. POLYTHÉRAPIE ANTICANCÉREUSE PAR RAYONNEMENT IONISANT FOCAL ET PERTURBATION CD47/SIRPα
EP4345101A1 (fr) 2022-09-29 2024-04-03 Irbm S.P.A. Dérivés d'azole utilisés en tant qu'inhibiteurs de shp2
TW202423442A (zh) 2022-10-21 2024-06-16 大陸商上海領泰生物醫藥科技有限公司 Kras g12d降解劑及其製備方法與應用
WO2024083256A1 (fr) 2022-10-21 2024-04-25 上海领泰生物医药科技有限公司 Agent de dégradation pan-kras, son procédé de préparation et son utilisation
CN115677660B (zh) * 2022-10-27 2024-05-03 中国药科大学 苯基脲类化合物及其制备方法、用途和药物组合物
AU2023409398A1 (en) 2022-12-22 2025-06-05 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
WO2024147703A1 (fr) * 2023-01-05 2024-07-11 주식회사 카나프테라퓨틱스 Inhibiteur de shp2 et ses utilisations
WO2024206858A1 (fr) 2023-03-30 2024-10-03 Revolution Medicines, Inc. Compositions pour induire une hydrolyse de ras gtp et leurs utilisations
PE20252777A1 (es) 2023-04-07 2025-12-22 Revolution Medicines Inc Inhibidores macrociclicos de ras
PE20260039A1 (es) 2023-04-07 2026-01-09 Revolution Medicines Inc Inhibidores macrociclicos de ras
EP4695260A1 (fr) 2023-04-11 2026-02-18 Gilead Sciences, Inc. Composés modulateurs de kras
KR20250169290A (ko) 2023-04-14 2025-12-02 레볼루션 메디슨즈, 인크. Ras 억제제의 결정형, 이를 함유하는 조성물 및 이의 사용 방법
WO2024216016A1 (fr) 2023-04-14 2024-10-17 Revolution Medicines, Inc. Formes cristallines d'un inhibiteur de ras
WO2024220917A1 (fr) 2023-04-21 2024-10-24 Gilead Sciences, Inc. Inhibiteurs de prmt5 et leurs utilisations
EP4704850A1 (fr) 2023-05-04 2026-03-11 Revolution Medicines, Inc. Polythérapie pour une maladie ou un trouble lié à ras
US20250042922A1 (en) 2023-06-30 2025-02-06 Gilead Sciences, Inc. Kras modulating compounds
TW202519517A (zh) 2023-07-26 2025-05-16 美商基利科學股份有限公司 Ｐａｒｐ７抑制劑
CN121568935A (zh) 2023-07-26 2026-02-24 吉利德科学公司 Parp7抑制剂
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025034919A1 (fr) 2023-08-08 2025-02-13 Quanta Therapeutics, Inc. Polythérapies avec des modulateurs de kras
TW202521120A (zh) * 2023-08-17 2025-06-01 大陸商北京加科思新藥研發有限公司 藥物組合物及其應用
WO2025054530A1 (fr) 2023-09-08 2025-03-13 Gilead Sciences, Inc. Dérivés polycycliques contenant une pyrimidine utilisés comme composés de modulation de kras g12d
WO2025054347A1 (fr) 2023-09-08 2025-03-13 Gilead Sciences, Inc. Composés de modulation de kras g12d
AU2024344161A1 (en) 2023-09-21 2026-03-26 Treeline Biosciences, Inc. Spirocyclic dihydropyranopyridine kras inhibitors
US20250154171A1 (en) 2023-10-12 2025-05-15 Revolution Medicines, Inc. Ras inhibitors
WO2025081291A1 (fr) * 2023-10-16 2025-04-24 Canwell Biotech Limited Dérivés de benzo [c] [1, 2] oxaborol-1(3h)-ol utilisés comme inhibiteurs de shp2, compositions et méthodes associées
WO2025096589A1 (fr) 2023-11-03 2025-05-08 Gilead Sciences, Inc. Inhibiteurs de prmt5 et leurs utilisations
WO2025106901A1 (fr) 2023-11-17 2025-05-22 Quanta Therapeutics, Inc. Polythérapies anticancéreuses avec un modulateur de kras et un inhibiteur de la voie rtk-mapk
WO2025137507A1 (fr) 2023-12-22 2025-06-26 Regor Pharmaceuticals, Inc. Inhibiteurs de sos1 et leurs utilisations
US20250230168A1 (en) 2023-12-22 2025-07-17 Gilead Sciences, Inc. Azaspiro wrn inhibitors
WO2025171296A1 (fr) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Inhibiteurs de ras
WO2025240847A1 (fr) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Inhibiteurs de ras
WO2025245003A1 (fr) 2024-05-21 2025-11-27 Gilead Sciences, Inc. Inhibiteurs de prmt5 et leurs utilisations
WO2025245127A1 (fr) 2024-05-21 2025-11-27 Treeline Biosciences, Inc. Inhibiteurs de dihydropyranopyrimidine kras spirocycliques
WO2025255438A1 (fr) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Procédés de traitement d'une maladie ou d'un trouble lié à la protéine ras
WO2025265060A1 (fr) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Compositions thérapeutiques et procédés de gestion d'effets liés au traitement
WO2026006747A1 (fr) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Inhibiteurs de ras
WO2026015796A1 (fr) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Méthodes de traitement d'une maladie ou d'un trouble lié à ras
WO2026015825A1 (fr) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Utilisation d'un inhibiteur de ras pour traiter le cancer du pancréas
WO2026015790A1 (fr) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Méthodes de traitement d'une maladie ou d'un trouble lié à ras
WO2026015801A1 (fr) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Méthodes de traitement d'une maladie ou d'un trouble liés à ras
WO2026039365A1 (fr) 2024-08-12 2026-02-19 Gilead Sciences, Inc. Composés de modulation de kras
WO2026050446A1 (fr) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Inhibiteurs de ras
WO2026060400A1 (fr) 2024-09-16 2026-03-19 Quanta Therapeutics, Inc. Polythérapies avec des modulateurs de kras

Family Cites Families (174)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3377826B2 (ja) 1993-05-06 2003-02-17 ヘキスト・アクチェンゲゼルシャフト 液晶組成物に使用するための新規化合物
ES2233982T3 (es) 1995-10-31 2005-06-16 Eli Lilly And Company Diaminas antitromboticas.
CA2361734A1 (fr) 1999-01-26 2000-10-12 Andre Rosowsky Composes pharmaceutiquement actifs et procedes d'utilisation
US7375125B2 (en) 1999-08-04 2008-05-20 Ore Pharmaceuticals, Inc. Melanocortin-4 receptor binding compounds and methods of use thereof
DE60137273D1 (de) 2000-10-20 2009-02-12 Eisai R&D Man Co Ltd Verfahren zur Herstellung von 4-Phenoxy chinolin Derivaten
EP1467736A2 (fr) 2001-12-21 2004-10-20 Bayer Pharmaceuticals Corporation Polytherapies antiangiogeneses a base de derives de pyridazine ou pyridine
US6855709B2 (en) 2002-02-22 2005-02-15 Pharmacia & Upjohn Company Pyridyl sulfone derivatives
DE10246657A1 (de) 2002-10-07 2004-04-15 Merck Patent Gmbh Chirales Phenolderivat, dieses enthaltendes Flüssigkristallmedium, Verfahren zur Herstellung eines Flüssigkristallmediums und elektrooptische Flüssigkristallanzeige
CN101077867B (zh) 2002-11-18 2012-10-10 坎莫森特里克斯公司 芳基磺酰胺
SE0203712D0 (sv) 2002-12-13 2002-12-13 Astrazeneca Ab Novel compounds
HRP20050690A2 (en) 2003-02-07 2006-08-31 Janssen Pharmaceutica N.V. Hiv inhibiting 1,2,4-triazines
CA2515544A1 (fr) 2003-02-11 2004-08-26 Kemia Inc. Composes destines au traitement d'une infection virale
GB2400101A (en) 2003-03-28 2004-10-06 Biofocus Discovery Ltd Compounds capable of binding to the active site of protein kinases
US20040242886A1 (en) 2003-04-30 2004-12-02 Sandeep Gupta Monocyclic diazodioxide based Bcl-2 protein antagonists related applications
US7393873B2 (en) 2003-07-02 2008-07-01 Merck & Co., Inc. Arylsulfonamide derivatives
WO2005005435A1 (fr) 2003-07-08 2005-01-20 Astrazeneca Ab Derives de spiro ′1-azabicyclo ′2.2.2!octan-3,5′-oxazolidin -2′-one! possedant une affinite avec le recepteur d'acetylcholine nicotinique alpha7
US7390907B2 (en) 2003-09-30 2008-06-24 Amgen Inc. Vanilloid receptor ligands and their use in treatments
GB0325956D0 (en) 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
TW200528459A (en) 2004-01-06 2005-09-01 Achillion Pharmaceuticals Inc Azabenzofuran substituted thioureas; inhibitors of viral replication
CN100465173C (zh) 2004-01-12 2009-03-04 西托匹亚研究有限公司 选择性激酶抑制剂
US7435831B2 (en) 2004-03-03 2008-10-14 Chemocentryx, Inc. Bicyclic and bridged nitrogen heterocycles
JP4845873B2 (ja) 2004-03-03 2011-12-28 ケモセントリックス インコーポレーティッド 二環式および架橋した窒素複素環
CN1934100A (zh) * 2004-03-23 2007-03-21 万有制药株式会社 取代喹唑啉或吡啶并嘧啶衍生物
US7285545B2 (en) 2004-05-03 2007-10-23 Boehringer Ingelheim Pharmaceuticals, Inc. Cytokine inhibitors
US8071624B2 (en) 2004-06-24 2011-12-06 Incyte Corporation N-substituted piperidines and their use as pharmaceuticals
US20070043057A1 (en) 2005-02-09 2007-02-22 Threshold Pharmaceuticals, Inc. Lonidamine analogs
AU2005298637B8 (en) 2004-10-29 2012-12-06 Janssen Sciences Ireland Uc HIV inhibiting bicyclic pyrimidine derivatives
WO2006063010A2 (fr) 2004-12-08 2006-06-15 Nuada, Llc Composes et procedes d'utilisation
GB0428082D0 (en) 2004-12-22 2005-01-26 Welcome Trust The Ltd Therapeutic compounds
DE602005020981D1 (de) 2004-12-23 2010-06-10 Mallinckrodt Inc Fluoreszente pyrazinderivate und verfahren zu deren anwendung bei der bewertung der nierenfunktion
US7622583B2 (en) 2005-01-14 2009-11-24 Chemocentryx, Inc. Heteroaryl sulfonamides and CCR2
CN101384183B (zh) 2005-02-04 2012-07-04 西诺米克斯公司 包含连接有杂芳基部分的化合物及其作为用于食物组合物的新型鲜味调节剂、促味剂和味觉增强剂的应用
ATE481407T1 (de) 2005-02-16 2010-10-15 Neurosearch As Neue diazabicyclische arylderivate und medizinische verwendung dafür
WO2007046867A2 (fr) 2005-05-19 2007-04-26 Xenon Pharmaceuticals Inc. Derives de piperidine et leurs utilisations comme agents therapeutiques
BRPI0610580B8 (pt) 2005-05-30 2021-05-25 Banyu Pharma Co Ltd composto derivado de piperidina
JP2007013804A (ja) 2005-07-01 2007-01-18 Mitsubishi Electric Corp 属性指定通信方法および通信装置
CA2606004A1 (fr) * 2005-08-02 2007-02-08 Neurogen Corporation Dipiperazinyl cetones et analogues apparentes
BRPI0618417A2 (pt) 2005-10-19 2012-07-31 Gruenenthal Chemie novos ligandos de receptores de vanilàide e seu uso para produzir medicamentos
WO2007057742A2 (fr) 2005-11-18 2007-05-24 Pfizer Products Inc. Nouveaux derives de piperazinone
JPWO2007063868A1 (ja) 2005-11-29 2009-05-07 東レ株式会社 アリールメチレンウレア誘導体及びその用途
AU2006328551A1 (en) 2005-12-21 2007-06-28 Janssen Pharmaceutica N.V. Substituted pyrazinone derivatives as alpha2c-adrenoreceptor antagonists
CN101405000A (zh) 2006-01-19 2009-04-08 艾博特公司 2-亚胺基-苯并咪唑化合物
CN101374835B (zh) 2006-01-30 2012-04-25 转化技术制药公司 作为PTPase抑制剂的取代的咪唑衍生物、组合物和使用方法
CA2645137A1 (fr) 2006-03-07 2007-09-13 James F. Blake Derives heterobicycliques de pyrazole et methodes d'utilisation
KR20080109789A (ko) 2006-04-20 2008-12-17 얀센 파마슈티카 엔.브이. 의약품으로 사용하기 위한 치환된 피라지논 유도체
WO2007135131A1 (fr) 2006-05-22 2007-11-29 Janssen Pharmaceutica N.V. Dérivés de pyrazinone substitués à utiliser comme médicament
US7838523B2 (en) 2006-09-11 2010-11-23 Cgi Pharmaceuticals, Inc. Certain substituted amides, method of making, and method of use thereof
AR063707A1 (es) 2006-09-11 2009-02-11 Cgi Pharmaceuticals Inc Determinadas amidas sustituidas, el uso de las mismas para el tratamiento de enfermedades mediadas por la inhibicion de la actividad de btk y composiciones farmacéuticas que las comprenden.
CA2664621A1 (fr) 2006-10-04 2008-04-10 F. Hoffmann-La Roche Ag Derives de pyrazine-2-carboxamide
DE102007018150A1 (de) 2007-04-16 2008-10-23 Grünenthal GmbH VR1-Rezeptor-Liganden und µ-Opioid-Rezeptor-Liganden zur Behandlung von Schmerz
JP2010518083A (ja) 2007-02-12 2010-05-27 メルク・シャープ・エンド・ドーム・コーポレイション ピペリジン誘導体
WO2008104077A1 (fr) 2007-02-28 2008-09-04 Methylgene Inc. Inhibiteurs à petite molécule de protéines arginine méthyltransférases (prmt)
CN101687040A (zh) 2007-03-01 2010-03-31 马林克罗特公司 整合光活性的小分子及其用途
CA2679659C (fr) 2007-03-01 2016-01-19 Novartis Ag Inhibiteurs de pim kinase et procedes de leur utilisation
WO2008112674A1 (fr) 2007-03-12 2008-09-18 Irm Llc Composés et compositions comme inhibiteurs de l'activité du récepteur cannabinoïde 1
EP2193130A1 (fr) 2007-09-06 2010-06-09 Array Biopharma, Inc. Pyrazolo-pyridines en tant qu'inhibiteurs de tyrosine kinase
WO2009036066A1 (fr) 2007-09-10 2009-03-19 Curis, Inc. Inhibiteurs du récepteur du facteur de croissance endothélial vasculaire (vegfr) contenant une fraction de liaison au zinc
JP5465177B2 (ja) 2007-09-20 2014-04-09 アイアールエム・リミテッド・ライアビリティ・カンパニー Ｇｐｒ１１９活性のモジュレーターとしての化合物および組成物
MX2010003849A (es) 2007-10-18 2010-04-27 Boehringer Ingelheim Int Antagonistas de cgrp.
EP2211864A1 (fr) 2007-10-24 2010-08-04 Merck Sharp & Dohme Corp. Antagonistes des canaux calciques de type t à base d'amide de pyrazinyle
WO2009108766A1 (fr) 2008-02-29 2009-09-03 Schering Corporation Modulateurs de l’activité gamma-secrétase pour le traitement de la maladie d'alzheimer
WO2009126584A1 (fr) 2008-04-07 2009-10-15 Amgen Inc. Pyridines/pyrimidines amino spirocycliques et disubstituées par gem en tant qu'inhibiteurs de cycle cellulaire
AR071619A1 (es) 2008-05-07 2010-06-30 Galapagos Nv Compuestos de pirazina fusionados utiles para el tratamiento de enfermedades degenerativas e inflamatorias y composiciones farmaceuticas que los contienen.
WO2009142732A2 (fr) 2008-05-20 2009-11-26 Cephalon, Inc. Dérivés pyridazinone substitués comme ligands des récepteurs de l'histamine-3 (h<sb>3</sb>)
MX2010013876A (es) 2008-06-20 2011-03-04 Metabolex Inc Agonistas de arilo grpr119 y sus usos .
NZ591176A (en) 2008-08-22 2012-11-30 Novartis Ag Pyrrolopyrimidine compounds as cdk inhibitors
WO2010036380A1 (fr) 2008-09-26 2010-04-01 Intellikine, Inc. Inhibiteurs hétérocycliques de kinases
CA2746307C (fr) 2008-12-17 2013-11-19 Amgen Inc. Composes aminopyridines et carboxypyridines en tant que inhibiteurs de phosphodiesterase 10
CA2744935A1 (fr) 2008-12-19 2010-06-24 Boehringer Ingelheim International Gmbh Nouveaux composes
CA2747795A1 (fr) 2008-12-25 2010-07-01 Taisho Pharmaceutical Co., Ltd. Derive d'isoquinoleine
BRPI1006943A2 (pt) 2009-01-22 2021-06-15 Unigene Laboratories Inc. peptídeo, composição farmacêutica que compreende o peptídeo e método para supressão do apetite, prevenção ou tratamento de uma condição de sobrepeso ou obesidade, ou para tratar diabetes
WO2010086613A1 (fr) 2009-01-30 2010-08-05 Betagenon Ab Composés utiles en tant qu'inhibiteurs tel que ampk
AU2010222289B2 (en) 2009-03-13 2013-07-11 Advinus Therapeutics Private Limited Substituted fused pyrimidine compounds
CN102596923B (zh) 2009-07-08 2015-04-29 波罗的海生物公司 1,2,4-噻唑烷-3-酮衍生物及其在癌症治疗中的用途
CN102753177A (zh) 2009-08-17 2012-10-24 纪念斯隆-凯特琳癌症中心 热休克蛋白结合化合物、组合物以及其制备和使用方法
WO2011027249A2 (fr) 2009-09-01 2011-03-10 Pfizer Inc. Dérivés de benzimidazole
MX2012004078A (es) 2009-10-09 2012-07-25 Irm Llc Compuestos y composiciones como moduladores de la actividad de gpr119.
US8759377B2 (en) 2009-11-23 2014-06-24 Vanderbilt University Substituted dioxopiperidines and dioxopyrrolidines as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
MX2012006776A (es) 2009-12-14 2012-10-05 Merck Patent Gmbh Inhibidores de la esfingosina quinasa.
CN104530079B (zh) 2009-12-18 2017-10-20 北京凯因科技股份有限公司 C型肝炎病毒复制的新型抑制剂
WO2011103091A1 (fr) 2010-02-18 2011-08-25 Transtech Pharma, Inc. Dérivés de phényl-hétéroaryle et procédés d'utilisation de ceux-ci
JP5918214B2 (ja) 2010-04-13 2016-05-18 ノバルティス アーゲー がんを治療するためのサイクリン依存性キナーゼ４またはサイクリン依存性キナーゼ（ｃｄｋ４／６）阻害剤およびｍｔｏｒ阻害剤を含む組合せ
MX344142B (es) 2010-04-29 2016-12-07 The Univ Of Edinburgh (8-aza-biciclico[3.2.1]oct-8-il)-[5-(1h-pirazol-4-il)-tiofen-3-il ]-metanonas 3, 3-disubstituidas como inhibidores de 1(beta)-hsd1.
US20110312996A1 (en) 2010-05-17 2011-12-22 Intermune, Inc. Novel inhibitors of hepatitis c virus replication
US8969349B2 (en) 2010-05-26 2015-03-03 Sunovion Pharmaceuticals Inc. Substituted quinoxalines and quinoxalinones as PDE-10 inhibitors
AU2011283684B2 (en) 2010-07-29 2015-08-27 Rigel Pharmaceuticals, Inc. AMPK-activating heterocyclic compounds and methods for using the same
JP2013230986A (ja) 2010-08-25 2013-11-14 Kyorin Pharmaceutical Co Ltd 新規ヒダントイン誘導体及びそれらを有効成分とする医薬
CN102432598A (zh) 2010-09-29 2012-05-02 江苏恒瑞医药股份有限公司 三环化合物、其制备方法及其在医药上的应用
WO2012068106A2 (fr) * 2010-11-15 2012-05-24 Exelixis, Inc. Benxazépines en tant qu'inhibiteurs de pi3k/mtor et leurs procédés d'utilisation et de fabrication
GB201020161D0 (en) 2010-11-26 2011-01-12 Almac Discovery Ltd Pharmaceutical compounds
CN105920010A (zh) 2010-12-14 2016-09-07 电泳有限公司 酪蛋白激酶1δ(CK1δ)抑制剂
EP2655334B1 (fr) 2010-12-22 2018-10-03 Eutropics Pharmaceuticals, Inc. Compositions et méthodes utilisables en vue du traitement de maladies
US20120184572A1 (en) 2011-01-13 2012-07-19 Metabolex, Inc. Aryl gpr119 agonists and uses thereof
AU2012249240A1 (en) 2011-04-29 2013-11-07 Icahn School Of Medicine At Mount Sinai Kinase inhibitors
US9586928B2 (en) 2011-05-16 2017-03-07 The Scripps Research Institute Modulators of the nuclear hormone receptor ROR
US20120316182A1 (en) * 2011-06-10 2012-12-13 Calcimedica, Inc. Compounds that modulate intracellular calcium
EP2554544A1 (fr) 2011-08-01 2013-02-06 Almirall, S.A. Dérivés de pyridin-2(1h)-one en tant qu'inhibiteurs de JAK
WO2013039851A1 (fr) 2011-09-12 2013-03-21 Mallinckrodt Llc Agents optiques permettant d'obtenir des images de métalloprotéases matricielles et de les visualiser
KR20140107340A (ko) 2011-12-12 2014-09-04 레셉토스, 인코포레이티드 당뇨병과 같은 치료를 위한 glp-1 수용체 조절제로서 작용하는 4 개의 사이클을 포함하는 카르복실산 유도체
WO2013124040A1 (fr) 2012-02-22 2013-08-29 Merck Patent Gmbh Milieu cristallin liquide
GB201204985D0 (en) 2012-03-21 2012-05-02 Genentech Inc Compounds
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
ES2743402T3 (es) 2012-04-25 2020-02-19 Raqualia Pharma Inc Derivados de amidas como bloqueadores TTX-S
WO2013167633A1 (fr) 2012-05-09 2013-11-14 Basf Se Composés d'acrylamide pour la lutte contre des animaux nuisibles invertébrés
CA2871388A1 (fr) 2012-06-27 2014-01-03 F. Hoffmann-La Roche Ag Composes 5-azaindazole et methodes d'utilisation
WO2014000178A1 (fr) 2012-06-27 2014-01-03 Merck Sharp & Dohme Corp. Dérivés de sulfamide et leurs méthodes d'utilisation permettant d'améliorer la pharmacocinétique d'un médicament
JP6254163B2 (ja) 2012-08-16 2017-12-27 ザ スクリプス リサーチ インスティテュート 新規カッパオピオイドリガンド
JOP20130273B1 (ar) 2012-09-11 2021-08-17 Genzyme Corp مثبطات انزيم (سينثاز) غلوكوسيل سيراميد
CN104869997B (zh) * 2012-11-09 2017-03-22 葛兰素史密斯克莱有限责任公司 作为二酰基甘油酰基转移酶抑制剂的新型化合物
EP2970116A1 (fr) 2013-03-15 2016-01-20 F. Hoffmann-La Roche AG Dérivés d'aryl sulfamide et de sulfamate comme modulateurs de rorc
CN105407889B (zh) 2013-03-15 2018-06-01 G1治疗公司 针对Rb阳性异常细胞增殖的HSPC节制性治疗
WO2014184074A1 (fr) 2013-05-15 2014-11-20 Basf Se Composés de n-(tétrazol-5-yl)- et n-(triazol-5-yl)hétarylcarboxamide substitués et leur utilisation en tant qu'herbicides
WO2014184014A1 (fr) 2013-05-15 2014-11-20 Basf Se Composés de n-(1,2,5-oxadiazol-3-yl)carboxamide et leur utilisation en tant qu'herbicides
GB201309508D0 (en) 2013-05-28 2013-07-10 Redx Pharma Ltd Compounds
JP6573604B2 (ja) 2013-06-11 2019-09-11 セルジーン インターナショナル ツー エスエーアールエル 新規なｇｌｐ−１レセプターモジュレーター
AU2014284279A1 (en) 2013-07-03 2016-02-18 Beth Israel Deaconess Medical Center, Inc. SHP2 inhibitors and methods of treating autoimmune and/or glomerulonephritis-associated diseases using SHP2 inhibitors
CN104341386A (zh) * 2013-07-23 2015-02-11 中国科学院上海药物研究所 一类芳基杂环小分子化合物、其衍生物及其制备方法和用途
EP3029031A4 (fr) 2013-07-30 2017-01-11 Takeda Pharmaceutical Company Limited Composé hétérocyclique
US9751881B2 (en) 2013-07-31 2017-09-05 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
US20150087673A1 (en) 2013-09-26 2015-03-26 Rigel Pharmaceuticals, Inc. Methods for using and biomarkers for ampk-activating compounds
AU2014334461B2 (en) 2013-10-08 2019-06-13 Qing-bin LU Non-platinum-based anti-cancer compounds for use in targeted chemotherapy
SI3060550T1 (sl) 2013-10-21 2019-09-30 Merck Patent Gmbh Heteroarilne spojine kot inhibitorji BTK in uporabe le-teh
EP2883934B1 (fr) 2013-12-16 2019-11-13 Merck Patent GmbH Support à cristaux liquides
WO2015091420A1 (fr) 2013-12-19 2015-06-25 Bayer Pharma Aktiengesellschaft Utilisation de dérivés de bipipéridinyle substitués comme antagonistes des alpha-2c-adrénorécepteurs
JP6523303B2 (ja) 2014-01-17 2019-05-29 ノバルティス アーゲー Ｓｈｐ２の活性を阻害するための１−ピリダジン／トリアジン−３−イル−ピペラジン／ピペリジン／ピロリジン誘導体およびその組成物
EP3094629B1 (fr) 2014-01-17 2018-08-22 Novartis AG Dérivés de 1-(triazin-3-yl/pyridazin-3-yl)-piper(-azine)idine et compositions les contenant pour l'inhibition de l'activité de shp2
JO3517B1 (ar) * 2014-01-17 2020-07-05 Novartis Ag ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
US9527835B2 (en) 2014-02-13 2016-12-27 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
PE20170245A1 (es) 2014-02-14 2017-03-30 Takeda Pharmaceuticals Co Pirazinas moduladoras de gpr 6
US10000469B2 (en) 2014-03-25 2018-06-19 Duke University Heat shock protein 70 (hsp-70) receptor ligands
PT3129374T (pt) 2014-04-07 2019-03-25 Netherlands Translational Res Center B V (5,6-dihidro)pirimido[4,5-e] indolizinas
KR20170007816A (ko) 2014-05-23 2017-01-20 에프. 호프만-라 로슈 아게 벤젠 설폰아마이드 유도체 및 RORc 조절인자로서의 이의 용도
WO2016015604A1 (fr) 2014-07-26 2016-02-04 Sunshine Lake Pharma Co., Ltd. Composés en tant que petites molécules inhibitrices de la cdk et leurs utilisations
WO2016022645A1 (fr) 2014-08-06 2016-02-11 Merck Sharp & Dohme Corp. Antagonistes hétérocycliques du récepteur du cgrp
WO2016022644A1 (fr) 2014-08-06 2016-02-11 Merck Sharp & Dohme Corp. Antagonistes hétérocycliques des récepteurs cgrp
EP2985334B1 (fr) 2014-08-15 2018-06-20 Merck Patent GmbH Milieu liquide cristallin
BR112017004334A2 (pt) * 2014-09-05 2018-08-07 Celgene Quanticel Res Inc inibidores de desmetilase específica de lisina-1.
WO2016040449A1 (fr) 2014-09-10 2016-03-17 Raze Therapeutics, Inc. Inhibiteurs de la 3-phosphoglycérate déshydrogénase) et leurs utilisations
TWI744225B (zh) 2015-02-27 2021-11-01 美商林伯士拉克許米公司 酪胺酸蛋白質激酶２（ｔｙｋ２）抑制劑及其用途
AU2016228660B2 (en) 2015-03-11 2020-05-07 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Substituted 2-hydrogen-pyrazole derivative serving as anticancer drug
CN107787226A (zh) 2015-03-25 2018-03-09 诺华股份有限公司 药物组合
EP3302057A4 (fr) 2015-06-04 2018-11-21 Kura Oncology, Inc. Méthodes et compositions d'inhibition de l'interaction de la ménine avec les protéines mll
AR104020A1 (es) 2015-06-04 2017-06-21 Kura Oncology Inc Métodos y composiciones para inhibir la interacción de menina con proteínas mill
US10287266B2 (en) 2015-06-19 2019-05-14 Novartis Ag Compounds and compositions for inhibiting the activity of SHP2
ES2824576T3 (es) * 2015-06-19 2021-05-12 Novartis Ag Compuestos y composiciones para inhibir la actividad de SHP2
US10975080B2 (en) 2015-06-19 2021-04-13 Novartis Ag Compounds and compositions for inhibiting the activity of SHP2
RU2604047C1 (ru) 2015-07-10 2016-12-10 Фортис Аксис, Закрытое Акционерное Общество Массажёр для воздействия на мышцы спины трех отделов позвоночника
IL257743B (en) 2015-09-17 2022-08-01 Marvin J Miller Benzyl amine-containing heterocyclic compounds and compositions useful against mycobacterial infection
WO2017114351A1 (fr) 2015-12-27 2017-07-06 Chongqing Fochon Pharmaceutical Co., Ltd. Inhibiteurs de certaines protéines kinases
WO2017156397A1 (fr) 2016-03-11 2017-09-14 Board Of Regents, The University Of Texas Sysytem Inhibiteurs hétérocycliques de ptpn11
WO2017162215A1 (fr) 2016-03-25 2017-09-28 正大天晴药业集团股份有限公司 Inhibiteur de cdk pyrrolopyrimidine substituée, composition pharmaceutique le comprenant et son utilisation
CN107286150B (zh) 2016-04-11 2020-07-07 中国科学院上海有机化学研究所 N-杂环类化合物、其中间体、制备方法、药物组合物和应用
CA3024706A1 (fr) 2016-05-31 2017-12-07 Board Of Regents, The University Of Texas System Inhibiteurs heterocycliques de ptpn11
KR102218333B1 (ko) * 2016-06-07 2021-02-22 자코바이오 파마슈티칼스 컴퍼니 리미티드 Shp2 억제제로서 유용한 신규한 헤테로환형 유도체
RU2021106500A (ru) * 2016-06-14 2021-04-16 Новартис Аг Соединения и композиции для подавления активности shp2
SG11201900157RA (en) 2016-07-12 2019-02-27 Revolution Medicines Inc 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric shp2 inhibitors
EP3290412A1 (fr) 2016-08-31 2018-03-07 Università degli Studi di Siena Inhibiteurs des nucléocapsides du vih-1
US11529347B2 (en) 2016-09-22 2022-12-20 Relay Therapeutics, Inc. SHP2 phosphatase inhibitors and methods of use thereof
WO2018089433A1 (fr) 2016-11-08 2018-05-17 Navitor Pharmaceuticals, Inc. Inhibiteurs de mtorc phényle et leurs utilisations
US20200016136A1 (en) 2017-01-03 2020-01-16 Viiv Healthcare Uk (No. 5) Limited Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication
AU2018207464B2 (en) * 2017-01-10 2020-05-14 Novartis Ag Pharmaceutical combination comprising an ALK inhibitor and a SHP2 inhibitor
EP3573606A4 (fr) * 2017-01-25 2020-11-25 Indiana University Research and Technology Corporation Prophylaxie et traitement de la leucémie myéloïde aiguë
HRP20241239T1 (hr) * 2017-03-23 2024-12-06 Jacobio Pharmaceuticals Co., Ltd. Novi heterociklički derivati korisni kao shp2 inhibitori
JP7175026B2 (ja) 2017-04-01 2022-11-18 晟科薬業（江蘇）有限公司 プロテインキナーゼ阻害剤としての１ｈ－イミダゾ［４，５－ｈ］キナゾリン系化合物
CN110891569A (zh) 2017-07-12 2020-03-17 范德堡大学 毒蕈碱性乙酰胆碱受体m4的拮抗剂
BR112020007058A2 (pt) 2017-10-12 2020-10-06 Revolution Medicines, Inc. compostos de piridina, pirazina, e triazina como inibidores de shp2 alostéricos
IL273924B2 (en) 2017-10-20 2024-07-01 Univ Vanderbilt Antagonists of the muscarinic acetylcholine receptor m4
CA3080941A1 (fr) 2017-12-22 2019-06-27 Dana-Farber Cancer Institute, Inc. Inhibiteurs de nek et procedes d'utilisation
JP7377207B2 (ja) 2018-01-29 2023-11-09 メルク パテント ゲーエムベーハー Ｇｃｎ２阻害剤およびその使用
KR20200116481A (ko) 2018-01-29 2020-10-12 메르크 파텐트 게엠베하 Gcn2 억제제 및 이의 용도
WO2019152454A1 (fr) 2018-01-30 2019-08-08 Research Development Foundation Inhibiteurs de shp2 et méthodes d'utilisation associées
BR112020015907A2 (pt) 2018-02-08 2020-12-15 Enyo Pharma Derivados de tiofeno fundidos e usos dos mesmos
KR102753101B1 (ko) 2018-03-02 2025-01-09 오츠카 세이야쿠 가부시키가이샤 약제학적 화합물
US11365188B2 (en) 2018-03-21 2022-06-21 Xibin Liao JAK inhibitors

Also Published As

Publication number Publication date
JP6751203B2 (ja) 2020-09-02
MX2021015074A (es) 2022-01-18
ES2908801T3 (es) 2022-05-04
MX2018015297A (es) 2019-08-12
CN112250670A (zh) 2021-01-22
EP3464272A4 (fr) 2019-04-24
EA202092442A3 (ru) 2021-08-31
SG10202110874TA (en) 2021-11-29
HRP20220251T1 (hr) 2022-04-29
KR20210141778A (ko) 2021-11-23
KR20210019607A (ko) 2021-02-22
SI3464272T1 (sl) 2022-05-31
CN112250670B (zh) 2021-06-08
HUE057838T2 (hu) 2022-06-28
CY1125042T1 (el) 2023-03-24
JP2019521181A (ja) 2019-07-25
AU2017276457B2 (en) 2019-10-03
US20190127378A1 (en) 2019-05-02
WO2017211303A1 (fr) 2017-12-14
CN109311848B (zh) 2022-02-01
CN114539273A (zh) 2022-05-27
RS62987B1 (sr) 2022-03-31
SG11201810983PA (en) 2019-01-30
US10858359B2 (en) 2020-12-08
EP4108659A1 (fr) 2022-12-28
AU2017276457A1 (en) 2019-01-24
PL3464272T3 (pl) 2022-03-28
PH12018550202A1 (en) 2019-10-21
DK3464272T3 (da) 2022-02-21
EP3464272A1 (fr) 2019-04-10
KR20230109185A (ko) 2023-07-19
LT3464272T (lt) 2022-03-10
PT3464272T (pt) 2022-03-11
MX2021015073A (es) 2022-01-18
EA202092441A1 (ru) 2021-05-21
MX388576B (es) 2025-03-20
EA202092442A2 (ru) 2021-06-30
JP2020189868A (ja) 2020-11-26
EP3464272B1 (fr) 2021-12-08
EA201990001A1 (ru) 2019-05-31
KR20190015756A (ko) 2019-02-14
JP2022153616A (ja) 2022-10-12
KR102218333B1 (ko) 2021-02-22
CA3026784A1 (fr) 2017-12-14
KR20220124275A (ko) 2022-09-13
CN109311848A (zh) 2019-02-05

Similar Documents

Publication Publication Date Title
MA49013A (fr) Nouveaux dérivés hétérocycliques utiles en tant qu&#39;inhibiteurs de shp2
MA45189A (fr) Nouveaux dérivés hétérocycliques utiles en tant qu&#39;inhibiteurs de shp2
MA47125A (fr) Dérivés de pyrazole en tant qu&#39;inhibiteurs de malt1
MA47123A (fr) Dérivés de benzooxazole en tant qu&#39;mmunomodulateurs
EP3416964A4 (fr) Dérivés de carboxamide utiles en tant qu&#39;inhibiteurs de rsk
MA46981A (fr) Dérivés de benzimidazole en tant qu&#39;inhibiteurs de bromodomaine
MA40774A (fr) Dérivés de diaryle-urée en tant qu&#39;inhibiteurs de kinase p38
MA51878A (fr) Composés d&#39;aminothiazole en tant qu&#39;inhibiteurs de c-kit
MA45153A (fr) Dérivés de carbonucléosides substitués utiles en tant qu&#39;agents anticancéreux
MA46339A (fr) Dérivés de cyanopyrrolidine ayant une activité en tant qu&#39;inhibiteurs de l&#39;usp 30
MA43169A (fr) Composés hétérocycliques utilisés en tant qu&#39;inhibiteurs de pi3k-gamma
MA42659A (fr) Dérivés hétéroaryle utilisés en tant qu&#39;inhibiteurs de parp
MA53150A (fr) Composés de benzimidazole en tant qu&#39;inhibiteurs de c-kit
MA45244A (fr) Pyridines substituées utilisées en tant qu&#39;inhibiteurs de dnmt1
ME03776B (fr) Dérivés de pyridin-2-(1h)-one-quinolinone en tant qu&#39;inhibiteurs d&#39;isocitrate déshydrogénase
MA55194A (fr) Composés hétérocycliques en tant qu&#39;immunomodulateurs
MA41140A (fr) Dérivés de 2,4-dioxo-quinazoline-6-sulfonamide en tant qu&#39;inhibiteurs de la parg
MA47086A (fr) Dérivés de dihydropyrimidine-carboxamide bicycliques utilisés en tant qu&#39;inhibiteurs de rho-kinase
MA54567A (fr) Pyridine et composés de pyridimine en tant qu&#39;inhibiteurs de pi3k-gamma
MA44502A (fr) Dérivés d&#39;indole substitués utilisés en tant qu&#39;inhibiteurs de réplication du virus de la dengue
EP2970119A4 (fr) Nouveaux dérivés d&#39;indole utiles en tant qu&#39;agents antidiabétiques
MA42592A (fr) Utilisation de dérivés de 2-(pyrazolopyridin-3-yl) pyrimidine en tant qu&#39;inhibiteurs de jak
MA44498A (fr) Dérivés d&#39;indoline substituée utilisés en tant qu&#39;inhibiteurs de la réplication du virus de la dengue
MA46878A (fr) Composés de benzodiazolium en tant qu&#39;inhibiteurs d&#39;enac
MA41341A (fr) Dérivés indole utilisés en tant qu&#39;inhibiteurs de la réplication du virus de la dengue